Introduction
Glaucoma affects 65 million people in the world and is the second main cause of blindness. Nearly 10% of ophthalmological disorders are related to this pathology.
This ocular disease is a neurodegenerative disease characterized by progressive degeneration of retinal ganglion cells [1] . It is characterized by structural changes in the optic disc and retinal fibre layer, as well as irreversible visual field loss. Reducing intraocular pressure helps to prevent the appearance of glaucoma and its progression in some patients; however, the reduction of intraocular pressure alone is not always effective.
Neuroprotection refers to the use of any treatment modality that prevents, retards or reverses neuronal cell death resulting from primary neuronal lesions [2, 3] . The concept of ocular neuroprotection has been advanced to treat the primary problem of glaucoma and/or neuronal death and is the name given to treatments directed at the loss of neurons. This address is the mechanism by which cell injury results in cell death or dysfunction, while lowering intraocular pressure, thus addressing the process responsible for cell injury.
Excessive activity of NMDA-type (N-methyl-D -aspartate) glutamatergic channels has been pointed to as a mechanism for neuronal injury in neurological disorders, including glaucoma and retinal disease. So memantine, an NMDA-type glutamatergic channel blocker, could be effective in reversing experimental excitotoxicity [4] .
Memantine (1-amino-3,5-dimethyladamantane) is a low-affinity voltage-dependent uncompetitive antagonist to glutamatergic NMDA receptors. This drug is able to inhibit the prolonged flow of Ca 2+ ions which represents the basis of neuronal excitotoxicity. Therefore, memantine may rescue neurons by its blockade of excessive glutamate receptor activation and can prevent ganglion cell death mediated by NMDA activation. Currently, studies have shown that treatment with memantine protected retinal ganglion cells in monkey models of glaucoma, reducing ganglion cell loss during treatment with this drug, measured by multifocal electroretinography and visual evoked responses [5] .
So far, clinical applications of these neuroprotective therapies have been conditional upon the highly systemic doses needed to achieve treatment concentrations in target tissue, such as the retinal ganglion cell layer.
An important goal is the development of a safe and effective means of chronic delivery of memantine to the posterior pole [6] [7] [8] .
At present, eye medications are given in different ways including topical, systemic, intraocular and periocular. When a systemic route (i.e. parenteral or oral) is used, the main concern is that drug doses are usually too high and side effects are exacerbated. On the other hand, when a drug is delivered topically (e.g. as eye drops), the fraction of dose remaining on the corneal surface is usually too low to achieve effective drug concentrations in the vitreous or other internal tissues [9, 10] . Therefore, in many cases, only 'invasive' forms of delivery (i.e. intravitreal or sub-Tenon routes) are capable of offering sufficient drug concentrations to the inner parts of the eye.
Specifically, nanoparticles (NPs) have been proven to come in useful in increasing the bioavailability of some active molecules in ophthalmology [11] [12] [13] [14] . In our case we selected a copolymer of methyl vinyl ether and maleic anhydride (Gantrez AN) as material for the preparation of NPs. This copolymer is widely used for pharmaceutical and medical purposes. In addition, the resulting NPs have demonstrated adequate abilities to control the release of the loaded drug and its biocompatibility [11] [12] [13] .
The objectives of this study were the preparation, characterization and in vitro evaluation of memantineloaded NPs. In addition, the clinical safety and retinal toxic response induced by these NPs after sub-Tenon and intravitreal administration were also evaluated.
Materials and Methods

Chemicals
Gantrez AN 119 [poly(methyl vinyl ether-comaleic anhydride) or poly(anhydride); MW 200,000] was a kindlgift by ISP (Barcelona, Spain). Memantine hydrochloride (grade 1 98% GC) was provided by Sigma-Aldrich (Barcelona, Spain). Acetone and ethanol were obtained from VWR Prolabo (Fontenay-sous-Bois, France) and phosphate-buffered saline from Gibco (Spain). oPhthalaldehyde was supplied by Molecular Probes (USA). All other chemicals used were of analytical grade and obtained from Merck (Madrid, Spain): methanol, 2-mercaptoethanol, boric acid, potassium hydroxide.
Preparation of Poly(anhydride) NPs
Poly(anhydride) NPs were prepared by a solvent displacement method [15] . Memantine was then added to the NPs by simple incubation in an aqueous medium at room temperature. Briefly, 10 ml of an ethanol-water mixture (1: 1, v/v) was dripped slowly into 5 ml of previously dissolved acetone containing 100 mg Gantrez AN. The organic solvents were removed under reduced pressure (Büchi R-144, Switzerland) and 10 mg of memantine hydrochloride, previously dissolved in 1 ml of water, was dispersed in the freshly prepared NPs and incubated for 30 min under magnetic stirring at room temperature. After this time, the resulting carriers were purified by centrifugation at 20,000 rpm for 20 min (sigma 3K30, Germany). The supernatants produced at the purification stage were collected and stored at -20 ° C in order to quantify the unloaded memantine. Finally, the pellets were resuspended in water, and the formulations were frozen and freeze-dried (Genesis 12EL, Virtis, USA) using sucrose (5% w/v) as a cryoprotector. The resulting formulation was termed memantine-loaded NPs.
Control NPs were prepared in the same way, in the absence of memantine and all batches of lyophilized NPs were stored at room temperature until use. That period was less than 3 months after fabrication. During this period of time, and when the NPs are stored as dry powder under room temperature, the stability is higher than 1 year.
Physicochemical Characterization of NPs
The particle size and the -potential of NPs were determined by photon correlation spectroscopy and electrophoretic laser Doppler anemometry, respectively, using a Zetamaster analyser system (Malvern Instruments, UK). Samples were diluted with double distilled water (measure of size) or 1 m M KCl (quantification of -potential) and examined at room temperature. All measurements were performed in triplicate.
The morphological characteristics of the NPs were examined by scanning electron microscopy (Zeiss DSM 940A SEM; Oberkochen, Germany) with a digital imaging capture system (Point Electronic GmbH, Halle, Germany). For this purpose, freeze-dried NPs were resuspended in ultrapure water and centrifuged at 20,000 rpm for 20 min at 4 ° C. Supernatants were then rejected and the pellets were mounted on a glass plate on metal stubs, using double-sided adhesive tape, and dried under hot flow air. Finally, the particles were coated with a thin layer of 12 nm of gold using an Emitech K550 sputtering device (Emitech, UK).
The yield of the NP preparation process was determined by gravimetry as described previously [16] . Briefly, Gantrez AN NPs, freshly prepared, were freeze-dried in the absence of the cryopro-tector. The yield was then calculated as the difference between the initial amount of polymer used to prepare NPs and the weight of the freeze-dried carriers.
Memantine Quantification
The amount of memantine added to the NPs was estimated by quantification of free memantine in the supernatants obtained during the purification phase using a fluorometric method with o -phthaldialdehyde, previously described [17] and validated [18] in terms of accuracy precision, specificity, linearity and detection limits.
A stock standard solution of o-phthalaldehyde was prepared by dissolving it in methanol (125 mg in 1.5 ml); 200 l of 2-mercaptoethanol was then added and the mixture taken up to a volume of 100 ml with borate buffer 0.4 M , titrated to pH 10.4 with KOH. This solution was stored in the dark at 4 ° C for not more than 1 week. A stock standard solution of memantine was prepared by directly dissolving commercially available reagent in doubly distilled water at a concentration of 100 g/ml. Working solutions were prepared by diluting the stock solution in water within a range of 0-50 g/ml.
In a set of 96 microtiter plates (Thermo Lab Systems, Vantaa, Finland) a volume of 50 l of working solution of memantine and 100 l of stock o -phthalaldehyde standard solution were added per well. After shaking the mixture for 60 s, fluorescence measurements were performed in a spectrophotometer at ex 340 nm and em 450 nm (Labsystems iEMS Reader MF, Finland).
For analysis, the supernatants (obtained from control NPs and memantine NPs) were defrosted at room temperature and diluted with ultrapure water (1: 60, v/v). Each sample was assayed in triplicate and no interferences from the presence of poly(anhydride) were found in the memantine analysis.
The amount of memantine associated with the NPs was calculated as the difference between the initial amount of memantine added and the amount of memantine determined in the supernatants. Thus, memantine loading was expressed as the amount of memantine (in micrograms) per milligram of NPs, whereas the association efficiency was determined as follows:
where Q associated is the total weight of memantine entrapped in the batch of NPs and Q initial is the initial weight of memantine added.
In vitro Release Study
In order to obtain the memantine release profile from poly(anhydride) NPs, 10 mg of lyophilized memantine NPs was dispersed in 1 ml phosphate-buffered saline (from Gibco TM , pH 7.4, containing 0.1% sodium azide as preservative) in Eppendorf tubes. The samples were incubated at 37 8 1 ° C under agitation in a VorTemp 56 TM Shaking Incubator (Labnet International Inc.) for specified periods of time. At each time interval, samples were assayed in triplicate and blank Gantrez AN NPs were used as a control. After the incubation, formulations were centrifuged at 17,000 rpm (Allegra TM X-22R Centrifuge, Beckman Coulter) for 20 min at 4 ° C. The memantine released was quantified in the supernatants, which were frozen at -80 ° C to be analysed later by the fluorometric method as described above. The release profile was expressed in terms of cumulative release in percentages, and plotted versus time.
Intravitreal and Sub-Tenon Administration
All injections were performed under general anaesthesia and aseptic conditions. General anaesthesia was achieved by intramuscular injection of 20 mg/kg of ketamine and 2 mg/kg of xylazine. All formulations were prepared under aseptic conditions
Sub-Tenon and Intravitreal Injection of NPs
The ocular sub-Tenon injection was carried out in the posterior space; the ocular surface was anaesthetized using topical 4% lidocaine drops. Adequate exposure was obtained by placing an eyelid speculum. The episcleral layer was entered using a 22-gauge trocar, with a 0.85 ! 25-mm intravenous cannula made of polytetrafluorethylene. The trocar was advanced approximately 12-15 mm into the episcleral space using a Zeiss Omi 99 microscope for visualization (Germany).
Intravitreous injections (0.1 ml) were given (in both eyes) in the approximate centre of the vitreous humour through a 27-gauge needle inserted below the superior rectus muscle, 2-3 mm from the corneal limbus. Previously, 0.1 ml of aqueous humour had been removed through a 27-gauge needle.
Eventually, 23 healthy New Zealand white rabbits, weighing 2-3 kg and aged 2-3 months, were selected and divided into two lots (1 and 2). In lot 1 thirteen animals were injected intravitreally with 1.6 mg of NPs in 0.1 ml of saline solution. This group of animals underwent bilateral enucleation at 24 h and 1, 2, 3 and 6 weeks after injection. In lot 2 ten animals received 4 mg of NPs in 0.3 ml of saline solution through the sub-Tenon space. This group of animals underwent bilateral enucleation at 1, 2 and 3 weeks after treatment.
One animal from each lot, intravitreally and via the sub-Tenon space, was used as a control and received only 0.1 ml and 0.3 ml of saline solution, respectively.
Clinical Evaluation
All rabbits from both the sub-Tenon and intravitreal groups were examined by slit lamp and indirect ophthalmoscopy before injection and at each successive predetermined time point (24 h, 1, 2, 3 and 6 weeks after injection for the intravitreal group, and 1, 2, 3 weeks after injection for the sub-Tenon group).
The aim of the visual inspection was to look for signs of inflammation at the anterior pole of the eye. The frequency and severity of conjunctival hyperaemia and chemosis, subconjunctival haemorrhage, iris vessel engorgement and cataract formation were evaluated using a scale of 0-3 for grading: grade 0 for normal; 1 for slight conjunctiva and iris congestion; 2 for moderate, and 3 for severe congestion or hyperaemia. Cataract formation was analysed and encoded in terms of cataract type (nuclear, cortical or subcapsular), extension (focal or diffuse) and density (grade 1 corresponded to a slight opacity that provided a clear view of the details of the fundus; grade 2 indicated moderate opacity; grade 3 was total opacity, making observing details of the retina difficult).
Vitreous clarity was evaluated by indirect ophthalmoscopic examination, and a scale of 0-4 was used for assessing this. Briefly, grade 0 indicated a clear view of retinal details, grade 1 corresponded to slight obscuration of retinal details; mild obscuration of retinal details with a clearer view of small retinal vessels was grade 2; moderate obscuration of retinal details with visibility of only large vessels corresponded to grade 3, while grade 4 indicated that only a faint view of the retina could be observed, only intuitively detecting the optic nerve papilla. Other findings such as vitreous haemorrhage, areas of local retinal inflammation, retinal detachment, retinal fibrosis or retinal haemorrhages were analysed in the fundus examination.
Histopathology
After the macroscopic analysis, all rabbits that had been injected through the sub-Tenon space and intravitreally were euthanized by intravenous injection of 20% sodium pentobarbital (30 mg/kg) and the eyes immediately enucleated. Previously, the globes had been marked off at the 12-o'clock position with a scleral silk 6-0 suture. Then the globes of periocular tissues were removed (muscle, Tenon capsule and conjunctiva) and washed with 0.9% saline solution. An aqueous paracentesis with a 27-gauge needle was undertaken to decrease intraocular pressure before the injection of 0.1 ml of fixative solution into the vitreous cavity. Afterwards, the globes were immersed in 10% formaldehyde fixative solution and sent to the Histology and Pathology Department of Veterinary Science, University of Zaragoza, for analysis.
The samples were processed and dyed with haematoxylin-eosin for light-microscopic examination and assessment of the following parameters: preservation of the architecture and normal proportions of the different eye structures, specifically the retinal layers (retinal pigment epithelium, inner and outer segments of photoreceptors, external nuclear layer, internal nuclear layer and ganglion cell layer). The presence of degeneration or necrotic processes, inflammatory signs and abnormal cell growths, such as atrophy, hyperplasia, neoplasia or neovascularization, was evaluated. A retinal morphometric analysis was performed using the Image Analysis System NIS-Elements ver. 3.07 (Nikon), to determine the neurosensory mean retinal thickness and both external and internal nuclear layers and ganglion cell layer thickness.
Other parameters such as optic disc oedema or retinal detachment were also analysed.
All procedures were carried out under Project License PI 07/07 approved by the in-house Ethics Committee for Animal Experiments from the University of Zaragoza (Spain). The care and use of animals was compliant with the Spanish Policy for Animal Protection RD1201/05, which meets the European Union Directive 86/609 on the protection of animals used for experimental and other scientific purposes.
Results
Characterization of Gantrez NPs
The main physicochemical properties of poly(anhydride) NP formulations are summarized in table 1 . Overall, the memantine-loaded NPs displayed a similar mean size to that of control NPs (186 vs. 179 nm, respectively). Furthermore, both control and memantine-loaded NPs displayed a quite homogeneous aspect as indicated by the low polydispersity index. The morphological analysis by SEM confirmed that memantine-loaded NPs consisted of a homogeneous population of almost spherical and rough particles ( fig. 1 ). On the other hand, slight differences in the negative surface charge were found for both types of NPs. Finally, the amount of drug associated with NPs was N P = Gantrez AN control NPs; Mem-NP = memantine-loaded NPs. Size and polydispersity index of the NP batches were assessed by photon correlation spectroscopy, the -potential by electrophoretic laser Doppler anemometry; yield of the polymer was transformed into NPs; memantine content indicates the amount of memantine loaded into NPs. Figure 2 shows the release profile of memantine from poly(anhydride) NPs under physiological conditions (phosphate-buffered saline, pH 7.4) over 15 days. These NPs displayed a biphasic release pattern characterized by an initial burst effect, followed by a continuous release of the drug over the course of at least 15 days. Initially, the amount of memantine released increased rapidly during the first 2 h. At this point about 35% of the loaded memantine had been released from the NPs. Levels of released memantine were then maintained constant for at least 7 days. On day 15, the amount of released memantine was slightly lower than on day 7, due probably to degrading. Tables 2 and 3 show the results of clinical examination after intravitreal and sub-Tenon administration of NPs. One and 2 weeks after treatment, variable degrees of conjunctival hyperaemia and chemosis -slight or mildwere found in all eyes in the sub-Tenon group; however, these had disappeared at the 3-week control. In 10 of 18 sub-Tenon-injected eyes, conjunctival haemorrhage was observed, coinciding with the injection site, around the superior rectus muscle insertion. Only 1 eye in the subTenon group showed vascular engorgement of the iris at week 2 after injection.
In vitro Release Study
Clinical Safety Ophthalmoscopic and Clinical Observations
Variable grades of cataract were observed in some eyes in the intravitreal group; however, this was not observed in the sub-Tenon group. In most cases, this manifested itself as a focal lens opacity located in the lower quadrants, in the posterior lens capsule, with higher density cataracts in eyes at the 3-week control but without this causing any difficulty for fundus examination. Immediately after the intravitreal injection, the formulation was visible as a whitish film in the vitreous. During the 6 weeks of follow-up, this film remained floating in the anterior vitreous next to the posterior surface of the lens and in the inferior vitreous forming whitish lumps. Four eyes that had received more traumatic NP intravitreal injections showed a vitreous haemorrhage, slightly obscuring the view of retinal details. Indirect ophthalmoscopy did not reveal any retinal lesion, such as retinal detachment or haemorrhage. None of the eyes showed optic disc inflammation or oedema. No signs of local retinal inflammation or retinal fibrosis were observed in either group.
Histopathology
The histological analysis of eyes after NP sub-Tenon injection showed a certain degree of distortion in the cytoarchitecture of the outer retina, with disruption of the retinal epithelium and outer segments of the photoreceptors. This phenomenon was also observed in the control group. Morphometric analysis of the retina revealed no significant differences between the intravitreal NP group and the control group as regards the thickness of the neural retina or outer nuclear layer, indicating no degeneration or atrophy of the retinal tissue. Figure 3 a-c shows the retinal appearance 1, 2 and 3 weeks after administration of unloaded sub-Tenon NPs. The architecture of the retinal layers was preserved in 5 of the 6 sub-Tenon eyes studied 3 weeks after administration. Only 1 eye showed a focus of retinal distortion, affecting mainly the ganglion cell layer, associated with oedema of the choroid; however, this fact was also observed in 1 of the control eyes. Inflammatory signs were present in the corneoscleral layer and ciliary body during the first 2 weeks after administration, reduced to minimal degrees 3 weeks after administration.
No signs of degeneration were found in the retina 24 h, 1, 3 or 6 weeks after intravitreal injection of NPs. A focus of choroid oedema and swelling of the retinal nerve fibre layer was detected in only 1 eye 24 h after the intravitreal injection, and in this eye the ciliary body presented mild inflammatory infiltration.
Unlike the sub-Tenon group, intravitreally injected eyes reveal inflammatory cells in the vitreous cavity. These inflammatory cells are composed mainly of monoand polynuclear cells at 24 h, and macrophages and giant multinuclear cells at 1 and 3 weeks, practically disappearing at 6 weeks ( fig. 4 ) . In only 1 case was the presence of cataract confirmed histologically.
Discussion
Memantine (1-amino-3,5-dimethyladamantane hydrochloride) is a novel, low-to-moderate-affinity, noncompetitive NMDA receptor antagonist of the open channel blocker type. Memantine is used in the treatment of Parkinson's disease, some types of movement disorders [19] and some dementia syndromes [20] , and has recently been described as a potential treatment for glaucoma [21] .
Different studies determining the presence of memantine in vitreous humour and plasma [22] , and the bio- Further experimental studies to determine the possibility of using a drug delivery system to maintain an efficient level of intravitreal memantine for a longer period of time in order to improve its use in treatment are now also being carried out by our research group. Here we can point to our initial experimental studies using Gantrez AN NPs as carriers of memantine by different ocular treatment pathways.
Memantine-loaded NPs were prepared by simple incubation of freshly prepared Gantrez AN NPs with memantine. After this incubation, the fraction of free drug was eliminated by purification and the resulting NPs dried by lyophilization.
NPs displayed a homogeneous mean size of about 180 nm. The preparative process enabled us to yield highly homogeneous NPs as corroborated by measuring the polydispersity index (lower than 0.2-0.3) and the SEM photographs ( fig. 1 ) . Interestingly, the -potential of memantine-loaded NPs was not significantly different from that observed for empty NPs. This fact can be explained by a combination of two phenomena: physical entrapment in the matrix and covalent link to the surface of NPs. In the former, at least a fraction of free memantine would be entrapped in the matrix of Gantrez AN NPs, which could be due to the swelling of the particles in aqueous media forming a 'sponge' structure [23] . In the latter, memantine would be bound to the surface of Gantrez AN NPs after reaction between amino groups of the drug with the anhydride residues of the polymer, as has been described previously for the coating of these NPs with albumin [24] or flagellin [25] . The in vitro release kinetics of memantine would be a consequence of this bimodal distribution of the drug within the NPs. In fact, in vitro release experiments of memantine were characterized by a very rapid burst effect of about 20%, followed by a continuous release of the drug over the course of at least 8 h.
In this study Gantrez NPs were administered by intravitreous and sub-Tenon routes, and both clinical safety and histological evaluations were carried out.
The visual inspection of the eyes' anterior segment revealed more inflammation, including conjunctival hyperaemia and chemosis in the sub-Tenon-injected eyes, probably due to greater manipulation of the periocular tissues in this route of administration. Nevertheless, signs of inflammation were mild to moderate and at the 3-week control had already disappeared. Cataract formation was observed in some eyes after intravitreal NP injection. In most cases, it was possible to observe focal lens opacity located in the lower quadrants at the posterior lens capsule. However, histological evidence of cataract, with fragmentation of cortical lens fibres and globules of denatured proteins were found in only 1 eye, suggesting that the lens opacities observed clinically -and interpreted as cataracts -were probably artefacts caused by the formulation of masses floating in the anterior vitreous in contact with the posterior surface of the lens, producing a false image of cataract. The formation of cataracts after intravitreal injections, as described above, suggests a traumatic origin associated with the injection technique. Moreover, posterior subcapsular cataract has been suggested to be more likely associated with elevated intra-ocular pressure after intravitreal injection of certain drugs [26] than with oxidative toxic damage induced by the NPs -an effect similar to the mechanism described for steroid-induced cataract. The NPs administered intravitreally as a suspension appeared floating as whitish films and lumps in the vitreous, whereas the eyes injected with saline solution or via the subTenon route appeared clear. The position of precipitates in the vitreous could be a key factor in the appearance of vitritis or local retinal damage [27] ; however, in our case indirect ophthalmoscopy did not reveal any sign of retinal damage such as fibrosis, haemorrhages, infiltrates or vascular proliferation. Only 1 of the eyes receiving NPs via the sub-Tenon space developed a focus of retinal distortion, affecting the ganglion cell layer and associated with oedema of the choroids. This was also observed in a control eye injected with saline solution, suggesting mechanical damage more than a chemical insult.
The histological assessment of the different ocular tissues suggested that Gantrez NPs were well tolerated after sub-Tenon administration. The injuries observed are typical of physical trauma and tend to disappear with the passage of time. We observed a few inflammatory cells (lymphocytes) in the periocular tissue at the injection site but not in the retina or other ocular tissues. The intravitreal route could also be considered tolerable in most cases, since signs of inflammation observed in the vitreous cavity and ciliary body during the first days tend to disappear 6 weeks later without affecting the retina layers. This can be considered as a normal self-defence mechanism of the eye. The retina appeared normal with no apparent structural changes. The disruption in the outer segments of the photoreceptors observed in histopathological sections of some eyes was probably produced by histological handling itself.
Our results suggest that rabbit eyes receiving poly(anhydride) NPs intravitreally or via the sub-Tenon route did not manifest any notable structural changes. It should be kept in mind that after intravitreal injection, NPs remain floating in the vitreous, and so this may interfere with patients' visual clarity. The advantage of sub-Tenon administration is that NPs are retained at the site of injection without penetrating the vitreous [28] . 
